PT2151235E - Formulação farmacêutica para o tratamento do trato digestivo superior - Google Patents
Formulação farmacêutica para o tratamento do trato digestivo superior Download PDFInfo
- Publication number
- PT2151235E PT2151235E PT08013091T PT08013091T PT2151235E PT 2151235 E PT2151235 E PT 2151235E PT 08013091 T PT08013091 T PT 08013091T PT 08013091 T PT08013091 T PT 08013091T PT 2151235 E PT2151235 E PT 2151235E
- Authority
- PT
- Portugal
- Prior art keywords
- effervescent tablet
- budesonide
- digestive tract
- upper digestive
- effervescent
- Prior art date
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 title description 7
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 58
- 229960004436 budesonide Drugs 0.000 claims abstract description 57
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 55
- 230000000694 effects Effects 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 23
- 239000002324 mouth wash Substances 0.000 claims description 23
- 229940051866 mouthwash Drugs 0.000 claims description 23
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 210000000214 mouth Anatomy 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 210000004051 gastric juice Anatomy 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 210000003800 pharynx Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 201000010927 Mucositis Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002245 particle Substances 0.000 description 9
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- -1 hydrogen carbonate compound Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XABNKAQYYIZELW-UHFFFAOYSA-K trisodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate carbonate Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].OC(=O)O.[Na+].[Na+] XABNKAQYYIZELW-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08013091A EP2151235B1 (de) | 2008-07-21 | 2008-07-21 | Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2151235E true PT2151235E (pt) | 2011-03-21 |
Family
ID=39951664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08013091T PT2151235E (pt) | 2008-07-21 | 2008-07-21 | Formulação farmacêutica para o tratamento do trato digestivo superior |
| PT98000235T PT2306988E (pt) | 2008-07-21 | 2009-07-02 | Formulação farmacêutica para o tratamento do tracto digestivo superior |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98000235T PT2306988E (pt) | 2008-07-21 | 2009-07-02 | Formulação farmacêutica para o tratamento do tracto digestivo superior |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8580300B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2151235B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5616889B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102159196B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE498396T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009273361B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2731312C (cg-RX-API-DMAC7.html) |
| CY (2) | CY1111878T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE502008002621D1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK2151235T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA018465B1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2358158T3 (cg-RX-API-DMAC7.html) |
| HR (2) | HRP20130171T1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL210779A (cg-RX-API-DMAC7.html) |
| ME (2) | ME01256B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ590593A (cg-RX-API-DMAC7.html) |
| PL (2) | PL2151235T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT2151235E (cg-RX-API-DMAC7.html) |
| RS (2) | RS51649B (cg-RX-API-DMAC7.html) |
| SI (2) | SI2151235T1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA100759C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010009961A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201100283B (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4790950B2 (ja) | 1999-06-14 | 2011-10-12 | コスモ・テクノロジーズ・リミテッド | 制御放出および味感遮蔽経口医薬組成物 |
| US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| ATE498396T1 (de) * | 2008-07-21 | 2011-03-15 | Falk Pharma Gmbh | Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes |
| EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
| JP2013506683A (ja) | 2009-10-01 | 2013-02-28 | アプタリス ファーマテク，インコーポレイテッド | 経口投与型コルチコステロイド組成物 |
| US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| FI2886108T4 (fi) * | 2013-12-23 | 2023-02-22 | Optimoitu farmaseuttinen koostumus ruokatorven tulehduksellisten muutosten hoitoon | |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4332394A1 (de) | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
| US5639475A (en) * | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
| US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| US5807578A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US5807577A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| GB9611364D0 (en) * | 1996-05-31 | 1996-08-07 | Smithkline Beecham Plc | Composition |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| JP3818789B2 (ja) * | 1999-02-18 | 2006-09-06 | 三菱化学フーズ株式会社 | 易崩壊性錠剤 |
| WO2003006629A1 (en) | 2001-07-11 | 2003-01-23 | Toshirou Sekine | Culturing method and device for photosynthetic microbes |
| WO2003026610A2 (en) * | 2001-09-25 | 2003-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of fast dissolving dosage form |
| CA2467747A1 (en) * | 2001-11-20 | 2003-05-30 | Dmi Biosciences, Inc. | Methods and products for oral care |
| JP2005526095A (ja) * | 2002-03-20 | 2005-09-02 | エラン ファーマ インターナショナル，リミティド | 脆砕性の低い急速溶解投与剤型 |
| SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| US20060013873A1 (en) * | 2004-07-16 | 2006-01-19 | Chih-Chiang Yang | Bioadhesive dosage form of steroids |
| US20070071817A1 (en) * | 2005-09-26 | 2007-03-29 | Phyzz, Inc. | Effervescent oral care compositions and method of use |
| JP2009526858A (ja) * | 2006-02-15 | 2009-07-23 | ティカ レーケメデル アーベー | コルチコステロイド溶液を製造する方法 |
| HUE030605T2 (hu) * | 2007-06-22 | 2017-05-29 | Dompe Farm Spa | Inhalációs alkalmazásra szolgáló pezsgõtabletták |
| BRPI0817927A2 (pt) * | 2007-10-01 | 2015-04-07 | Lesvi Laboratorios Sl | Comprimidos orodispersiveis |
| ATE498396T1 (de) * | 2008-07-21 | 2011-03-15 | Falk Pharma Gmbh | Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes |
| EP2440210A4 (en) * | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
-
2008
- 2008-07-21 AT AT08013091T patent/ATE498396T1/de active
- 2008-07-21 ES ES08013091T patent/ES2358158T3/es active Active
- 2008-07-21 RS RS20110100A patent/RS51649B/sr unknown
- 2008-07-21 EP EP08013091A patent/EP2151235B1/de active Active
- 2008-07-21 ME MEP-2011-46A patent/ME01256B/me unknown
- 2008-07-21 SI SI200830187T patent/SI2151235T1/sl unknown
- 2008-07-21 DK DK08013091.7T patent/DK2151235T3/da active
- 2008-07-21 DE DE502008002621T patent/DE502008002621D1/de active Active
- 2008-07-21 PL PL08013091T patent/PL2151235T3/pl unknown
- 2008-07-21 PT PT08013091T patent/PT2151235E/pt unknown
-
2009
- 2009-02-07 UA UAA201101686A patent/UA100759C2/uk unknown
- 2009-07-02 CN CN2009801358800A patent/CN102159196B/zh not_active Expired - Fee Related
- 2009-07-02 DK DK09800023.5T patent/DK2306988T3/da active
- 2009-07-02 CA CA2731312A patent/CA2731312C/en not_active Expired - Fee Related
- 2009-07-02 EA EA201100229A patent/EA018465B1/ru not_active IP Right Cessation
- 2009-07-02 PL PL09800023T patent/PL2306988T3/pl unknown
- 2009-07-02 JP JP2011519101A patent/JP5616889B2/ja not_active Expired - Fee Related
- 2009-07-02 SI SI200930502T patent/SI2306988T1/sl unknown
- 2009-07-02 RS RS20130071A patent/RS52662B/sr unknown
- 2009-07-02 PT PT98000235T patent/PT2306988E/pt unknown
- 2009-07-02 ES ES09800023T patent/ES2399321T3/es active Active
- 2009-07-02 US US13/054,844 patent/US8580300B2/en not_active Expired - Fee Related
- 2009-07-02 EP EP09800023A patent/EP2306988B1/de not_active Revoked
- 2009-07-02 NZ NZ590593A patent/NZ590593A/en unknown
- 2009-07-02 HR HRP20130171AT patent/HRP20130171T1/hr unknown
- 2009-07-02 ME MEP-2013-22A patent/ME01494B/me unknown
- 2009-07-02 AU AU2009273361A patent/AU2009273361B2/en not_active Ceased
- 2009-07-02 WO PCT/EP2009/058320 patent/WO2010009961A1/de not_active Ceased
-
2011
- 2011-01-11 ZA ZA2011/00283A patent/ZA201100283B/en unknown
- 2011-01-20 IL IL210779A patent/IL210779A/en active IP Right Grant
- 2011-03-11 CY CY20111100274T patent/CY1111878T1/el unknown
- 2011-03-23 HR HR20110208T patent/HRP20110208T1/hr unknown
-
2013
- 2013-02-26 CY CY20131100174T patent/CY1113719T1/el unknown
- 2013-10-23 US US14/061,578 patent/US20140079646A1/en not_active Abandoned
-
2014
- 2014-07-30 JP JP2014155149A patent/JP6209495B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2151235E (pt) | Formulação farmacêutica para o tratamento do trato digestivo superior | |
| ES2742525T3 (es) | Composiciones de corticosteroides administradas oralmente | |
| ES2791715T3 (es) | Películas sublinguales | |
| BRPI0818118B1 (pt) | Composição farmacêutica na forma de uma suspensão aquosa estabilizada de carisbamato e seu processo de formação | |
| EP4076380B1 (en) | Transmucosal therapeutic system containing agomelatine | |
| KR101312331B1 (ko) | 약학적 코 제형물 및 이의 이용 방법 | |
| BR112019027286A2 (pt) | formulação de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
| ES2716990T5 (es) | Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago | |
| BR112020015646A2 (pt) | Formulações intranasais de epinefrina e métodos para o tratamento de doença | |
| JP5561885B2 (ja) | ミルタザピンの新しい配合物 | |
| KR102628438B1 (ko) | 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 함유하는 약제학적 조성물 | |
| HK1149907B (en) | Pharmaceutical formulation for treating the upper digestive tract | |
| HK1136190A1 (en) | Pharmaceutical formulation for treating the upper digestive tract | |
| HK1136190B (en) | Pharmaceutical formulation for treating the upper digestive tract | |
| TR201612582A1 (tr) | Oral farmasöti̇k terki̇pler | |
| HK40110942A (en) | Transmucosal therapeutic system containing agomelatine | |
| TR201612324A1 (tr) | Solunum Yolu Hastalıklarında Kullanılan Farmasötik Terkipler | |
| ES2548090T3 (es) | Uso de una suspensión oral que comprende acetato de megestrol para el tratamiento de asma bronquial | |
| HK40082930A (en) | Transmucosal therapeutic system containing agomelatine | |
| WO2021249578A2 (zh) | 预防治疗哮喘或慢阻肺或过敏性疾病等的药物 | |
| WO2020003107A1 (en) | Low dose oral pharmaceutical composition of pirfenidone or salt thereof |